Call for Abstracts

64th ASH Annual Meeting and Exposition

  • Letter From ASH Secretary
  • Eligibility
  • Responsibilities
  • Technical Requirements
  • Before you Begin
  • Submission Process
  • FAQs

Dear abstract authors,

We are very pleased you are interested in submitting your research abstract to the 2022 American Society of Hematology meeting -- the premier global meeting in hematology -- being held in New Orleans, December 10-13, 2022. Before you begin the process, I would like to highlight several changes in our abstract format and in abstract categories and give you more information regarding requirements for presentation of abstracts at the annual meeting. Your close attention is necessary to give your abstract the best chance for inclusion in the annual meeting as an oral session presentation or poster.

  • Abstracts will be limited to 3,800 characters to be accommodated on our digital platform.
  • Abstracts may include no more than two panels of additional content. A "panel" would be defined as a table or a single graphical representation of data (ie equivalent to a figure panel in a paper, not to a multi-panel figure).

Please carefully review all descriptions before selecting a category for your abstract. Categories are updated every year to respond to submission trends and to encompass new topics. This year, updates have been made to multiple category descriptions with significant changes as follows:

  • The 300s Categories (Hemostasis, Thrombosis and Vascular Biology) have all been reorganized, with inclusion of basic/translational studies of thrombosis in category 301, and clinical and epidemiologic aspects of thrombotic microangiopathies and of COVID-19 in category 331, among other changes.
  • Category 506 (Bone Marrow Microenvironment), now encompasses interactions of the microenvironment with both normal and leukemia stem cells.
  • Category 508 has been split into 508 (Bone Marrow Failure: Acquired) and 509 (Bone Marrow Failure and Cancer Predisposition Syndromes: Inherited).
  • Categories 602 and 603 have been reorganized around lineage targets rather than oncogenic mechanism, and now consist of 602 (Myeloid Oncogenesis: Basic) and 603 (Lymphoid Oncogenesis: Basic).
  • Category 704 has been split into 704 (Cellular Immunotherapies: Early Phase Clinical Trials) and 705 (705 Late Phase and Commercially Available Therapies).

Note that ASH reserves the right to move your abstract to a more appropriate category if misplacement is noted by the Secretary during abstract processing; however, correct categorization at the time of submission is the author's responsibility and will ensure the highest quality review process.

ASH plans to hold a hybrid in-person/virtual meeting at ASH 2022 in New Orleans. However ASH requires that abstract presenters of oral or poster presentations attend the meeting and present their abstract and respond to questions in person. If the first author is unable to attend in person, another abstract author able to attend in person may be substituted as the presenter. We realize decisions about attendance may not be feasible before the abstract submission deadline and we will accommodate necessary changes as needed. ASH is continually re-assessing the status of our upcoming meetings in light of the COVID-19 pandemic. We encourage you to monitor our annual meeting webpages to stay abreast of the latest updates. Public health guidance on preventing the transmission of COVID-19 continues to evolve, and ASH will, at minimum, base its on-site protocols on the latest guidance from the CDC in addition to local regulations in New Orleans.

  • Due to the uncertain nature of the ongoing COVID-19 pandemic and technical complexities of presenting a hybrid in-person/virtual meeting, we also require that you submit a pre-recorded version of your presentation by November 16 as an emergency back-up should it become necessary to pivot to the recording due to circumstances beyond ASH's control.
  • ASH reminds authors that the last date to withdraw abstracts from the annual meeting is September 16, 2022.

The link to our submission process is provided here for ease of access. For questions about the abstract submission process, contact

We look forward seeing you in New Orleans and hearing about your current research in hematology!


Cynthia Dunbar, MD
ASH Secretary